Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:18
作者
Kontorinis, Georgios [1 ,2 ]
Nichani, Jaya [1 ]
Freeman, Simon R. [1 ]
Rutherford, Scott A. [3 ]
Mills, Samantha [4 ]
King, Andrew T. [3 ]
Mawman, Deborah [1 ]
Huson, Sue [5 ]
O'Driscoll, Martin [1 ]
Gareth Evans, D. [5 ]
Lloyd, Simon K. W. [1 ,6 ,7 ]
机构
[1] Cent Manchester Univ Hosp, NHS Fdn Trust, Univ Dept Otolaryngol, Manchester M13 9PL, Lancs, England
[2] Southern Teaching Hosp, Inst Neurosci, Dept Otolaryngol, Glasgow, Lanark, Scotland
[3] Salford Royal NHS Fdn Trust, Dept Neurosurg, Manchester, Lancs, England
[4] Salford Royal NHS Fdn Trust, Dept Neuroradiol, Manchester, Lancs, England
[5] Cent Manchester Univ Hosp, NHS Fdn Trust, Dept Med Genet, Manchester M13 9PL, Lancs, England
[6] Univ Manchester, Sch Canc, Manchester M13 9PL, Lancs, England
[7] Univ Manchester, Enabling Serv, Manchester M13 9PL, Lancs, England
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol; VESTIBULAR SCHWANNOMAS; NATURAL-HISTORY; CONSERVATIVE MANAGEMENT; COCHLEAR IMPLANTATION; UNITED-KINGDOM; GROWTH; PRESERVATION; NF2;
D O I
10.1007/s00405-014-3317-7
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8-21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p = 0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7-19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients' age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:8
相关论文
共 50 条
  • [31] Bilateral Spontaneous Regression of Vestibular Schwannoma in Neurofibromatosis Type 2
    Sebok, Martina
    van Niftrik, Christiaan Hendrik Bas
    Bozinov, Oliver
    WORLD NEUROSURGERY, 2018, 113 : 195 - 197
  • [32] Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
    Plotkin, Scott R.
    Stemmer-Rachamimov, Anat O.
    Barker, Fred G., II
    Halpin, Chris
    Padera, Timothy P.
    Tyrrell, Alex
    Sorensen, A. Gregory
    Jain, Rakesh K.
    di Tomaso, Emmanuelle
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (04) : 358 - 367
  • [33] Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms
    Ruggieri, Martino
    Pratico, Andrea Domenico
    Evans, Dafydd Gareth
    SEMINARS IN PEDIATRIC NEUROLOGY, 2015, 22 (04) : 240 - 258
  • [34] Hearing Improvement after Bevacizumab for Neurofibromatosis Type 2 REPLY
    Plotkin, Scott R.
    Halpin, Chris
    di Tomaso, Emmanuelle
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (18) : 1810 - 1811
  • [35] Hearing Loss: Diagnosis and Management
    Lasak, John M.
    Allen, Patrick
    Mcvay, Tim
    Lewis, Douglas
    PRIMARY CARE, 2014, 41 (01): : 19 - +
  • [36] Hearing rehabilitation in neurofibromatosis type 2 patients: Cochlear versus auditory brainstem implantation
    Vincenti, Vincenzo
    Pasanisi, Enrico
    Guida, Maurizio
    Di Trapani, Giuseppe
    Sanna, Mario
    AUDIOLOGY AND NEURO-OTOLOGY, 2008, 13 (04) : 273 - 280
  • [37] Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions
    Yuan, Ruofei
    Wang, Bo
    Wang, Ying
    Liu, Pinan
    ONCOLOGY AND THERAPY, 2024, 12 (02) : 257 - 276
  • [38] Hearing Rehabilitation in Patients With Neurofibromatosis Type 2: The Quebec's Experience With Auditory Implants
    Khneisser, Edwina
    Bussieres, Richard
    Cote, Mathieu
    Philippon, Daniel
    Fradet, Gaetan
    Cote, Martin
    Lessard, Nathalie
    Champagne, Pierre-Olivier
    Trudel, Mathieu
    OTOLOGY & NEUROTOLOGY, 2023, 44 (08) : E621 - E627
  • [39] The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2
    Alanin, Mikkel Christian
    Klausen, Camilla
    Caye-Thomasen, Per
    Thomsen, Carsten
    Fugleholm, Kaare
    Poulsgaard, Lars
    Lassen, Ulrik
    Mau-Sorensen, Morten
    Hofland, Kenneth Francis
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2015, 272 (12) : 3627 - 3633
  • [40] Incidence of Hearing Loss in Patients With Neurofibromatosis Type 1 at a Tertiary Care Pediatric Hospital
    Yun, Alice
    Grif, Amanda M.
    Kim, Hae-Young
    Ullrich, Nicole J.
    Licameli, Greg R.
    PEDIATRIC NEUROLOGY, 2024, 159 : 35 - 40